Jeff Martin
Stock Analyst at Roth MKM
(2.29)
# 2,403
Out of 4,829 analysts
64
Total ratings
27.27%
Success rate
18.19%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OSIS OSI Systems | Maintains: Buy | $224 → $245 | $226.72 | +8.06% | 16 | May 2, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $4.11 | +118.98% | 1 | Mar 20, 2025 | |
| NVEE NV5 Global | Maintains: Buy | $27 → $28 | $19.86 | +40.98% | 7 | Feb 21, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $41.45 | +8.56% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $25.58 | +17.28% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $25.13 | +71.11% | 5 | Aug 8, 2024 | |
| FC Franklin Covey Co. | Reiterates: Buy | $50 | $22.56 | +121.63% | 7 | Jun 27, 2024 | |
| PERI Perion Network | Downgrades: Neutral | $35 → $13 | $9.59 | +35.56% | 7 | Apr 9, 2024 | |
| NSP Insperity | Maintains: Buy | $144 → $147 | $69.11 | +112.70% | 8 | Apr 27, 2023 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.26 | +457,042.86% | 2 | Nov 15, 2017 |
OSI Systems
May 2, 2025
Maintains: Buy
Price Target: $224 → $245
Current: $226.72
Upside: +8.06%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $4.11
Upside: +118.98%
NV5 Global
Feb 21, 2025
Maintains: Buy
Price Target: $27 → $28
Current: $19.86
Upside: +40.98%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $41.45
Upside: +8.56%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $25.58
Upside: +17.28%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $25.13
Upside: +71.11%
Franklin Covey Co.
Jun 27, 2024
Reiterates: Buy
Price Target: $50
Current: $22.56
Upside: +121.63%
Perion Network
Apr 9, 2024
Downgrades: Neutral
Price Target: $35 → $13
Current: $9.59
Upside: +35.56%
Insperity
Apr 27, 2023
Maintains: Buy
Price Target: $144 → $147
Current: $69.11
Upside: +112.70%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.26
Upside: +457,042.86%